Pharmacological and electrical cardioversion of atrial fibrillation is associated with a >10-fold increased risk of thromboembolic events clustering within 7 days following sinus rhythm restoration.
How should anticoagulation and thromboembolic risk be managed in patients undergoing pharmacological and electrical cardioversion of atrial fibrillation?
This review highlights that thromboembolic complications post-cardioversion are primarily driven by atrial stunning rather than preexisting thrombi, emphasizing the need for appropriate periprocedural anticoagulation.
Pharmacological and electrical cardioversion of atrial fibrillation (AF) is associated with markedly increased (>10-fold) risk of thromboembolic events clustering within 7 days following sinus rhythm restoration. Current evidence indicates that post-cardioversion thrombus formation from atrial stunning, rather than preexisting thrombus, causes most thromboembolic complications. Risk factors include traditional CHA
Johner et al. (Wed,) conducted a review in Atrial fibrillation. Pharmacological and electrical cardioversion was evaluated on Thromboembolic events. Pharmacological and electrical cardioversion of atrial fibrillation is associated with a >10-fold increased risk of thromboembolic events clustering within 7 days following sinus rhythm restoration.